Larkberget

Larkberget Financial Leverage

The Financial Leverage (Equity Multiplier) of Larkberget (LARK.ST) as of Oct 17, 2026 is 1.02. In the previous year, Financial Leverage (Equity Multiplier) was 1.06 — a change of -3.56% (lower).

Financial Leverage

1.02

YoY

-3.56%

Last updated:

Financial Leverage (Equity Multiplier) of Larkberget is 2025 1.02 . Financial Leverage (Equity Multiplier) of Larkberget was 2024 1.06 . It decreases by -3.56% lower compared to the previous year.

The Larkberget Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.72 SEK
Jan 1, 2019
2.37 SEK
Jan 1, 2020
1.11 SEK
Jan 1, 2021
1.05 SEK
Jan 1, 2022
1.04 SEK
Jan 1, 2023
1.04 SEK
Jan 1, 2024
1.06 SEK
Jan 1, 2025
1.02 SEK
The Larkberget Financial Leverage history
YEARFinancial LeverageYoY
1.02-3.56%
1.06+2.35%
1.04-0.42%
1.04-0.96%
1.05-5.54%
1.11-53.15%
2.37+38.23%
1.72+37.35%
1.25+4.29%
1.20+12.28%
1.07-3.21%
1.10—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Larkberget Stock analysis

What does Larkberget do? Larkberget AB, trading under the ticker LARK.ST, is a biotechnology company based in Lidingoe, Sweden. The company, which is listed on the Stockholm Stock Exchange, went public through an IPO on May 25, 2015. Larkberget AB operates within the health care sector, specifically in the biotechnology industry. The company's website is https://combigene.com/. According to the provided information, Larkberget AB is engaged in the development of new treatments for neurological diseases. The firm's platform involves the use of gene therapy vectors to deliver combinations of transgenes encoding neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors. These vectors are designed for the treatment of neurological and psychiatric diseases in both humans and animals. The company focuses on developing an epilepsy treatment using an adeno-associated virus (AAV) vector that carries transgenes for the neurotransmitter NPY and its receptor, the G protein-coupled receptor Y2. The company's headquarters are located in Lidingoe, near Stockholm. Larkberget is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Larkberget stock

Financial Leverage (Equity Multiplier) of Larkberget is 1.02 in 2025.

Financial Leverage (Equity Multiplier) of Larkberget changed from 1.06 to 1.02, representing a -3.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Larkberget since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Larkberget with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Larkberget

All Key Metrics — Larkberget